From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Clopidogrel and Proton-Pump Inhibitors

Risk for adverse cardiac events was elevated in patients taking both medications.

Prior biochemical studies have suggested that proton-pump inhibitors (PPIs) reduce the inhibitory effect of clopidogrel on platelet aggregation. A recent FDA review raised concerns about this issue, but data were insufficient to make a specific recommendation. In this study, a Veterans Affairs database was used to retrospectively assess this interaction clinically in 8205 patients discharged with acute coronary syndromes (ACS); 5244 (64%) were taking both clopidogrel and a PPI, and the rest were taking clopidogrel alone. Medication use was assessed by pharmacy prescription data.

At a mean follow-up of roughly 18 months, death or rehospitalization for ACS had occurred in 1561 patients (30%) taking both medications and 615 (21%) of patients taking only clopidogrel. In analyses adjusted for about 25 demographic and clinical variables, risk for death or rehospitalization was roughly 25% higher in patients taking both medications (86% higher for recurrent ACS, 49% higher for revascularization procedures, but no difference for death alone).

Comment: As with any retrospective analysis, there are confounders for which statistical adjustment might not be fully adequate, so prospective clinical trials are needed to confirm this result. However, based on plausible biological mechanisms (e.g., inhibition by PPIs of the cytochrome P450 enzyme system responsible for the active metabolite of clopidogrel), clinicians should be more parsimonious in their use of PPIs for specific indications, rather than using them for routine prophylaxis, as is often done.

Thomas L. Schwenk, MD

Published in Journal Watch General Medicine March 12, 2009

Citation(s):

Ho PM et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 Mar 4; 301:937.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2009. Massachusetts Medical Society. All rights reserved.